ஜனநாயகவாதிகள் கரோலின் மலோநீ News Today : Breaking News, Live Updates & Top Stories | Vimarsana
House Committees to Investigate New Alzheimer Disease Drug Approval
neurologyadvisor.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from neurologyadvisor.com Daily Mail and Mail on Sunday newspapers.
House Committees to Investigate New Alzheimer Disease Drug Approval
psychiatryadvisor.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from psychiatryadvisor.com Daily Mail and Mail on Sunday newspapers.
Biogen s Aduhelm: US lawmakers launch investigation into FDA approval and price of new Alzheimer s drug
cnn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from cnn.com Daily Mail and Mail on Sunday newspapers.
House Committees to Investigate New Alzheimer Disease Drug Approval We have serious concerns about the steep price of Biogen s new Alzheimer s drug Aduhelm and the process that led to its approval, said House Democrats Carolyn Maloney and Frank Pallone Jr. (Credit: Getty Images.)
HealthDay News â The US Food and Drug Administration’s controversial approval of a new drug for Alzheimer disease, along with its high price, is now being investigated by two House committees.
“We have serious concerns about the steep price of Biogen’s new Alzheimer’s drug Aduhelm and the process that led to its approval despite questions about the drug’s clinical benefit,” House Democrats Carolyn Maloney and Frank Pallone Jr. said in a statement from the Committee on Oversight and Reform and the Committee on Energy and Commerce,
By Jacqueline Howard, CNN
Two House committees have launched an investigation into the approval and pricing of the Alzheimer’s disease drug aducanumab, made by the company Biogen and sold under the brand name Aduhelm.
The US Food and Drug Administration approved the drug earlier this month under its “accelerated approval” program, although an FDA advisory committee concluded last year that there was not enough evidence to support the effectiveness of the treatment.
Biogen announced in early June that the wholesale cost of treatment which requires an infusion once every four weeks is about $4,312 per infusion, making the annual cost about $56,000 for a high dose.